2-甲基-6-苯基乙炔基吡啶盐酸盐 | 219911-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-6-苯基乙炔基吡啶盐酸盐
• 中文别名: 2-甲基-6-(苯基乙炔基)吡啶盐酸盐
• 英文名称: 2-methyl-6-(phenylethynyl)pyridine hydrochloride
• 英文别名: MPEP；6-methyl-2-(phenylethynyl)pyridine hydrochloride；MPEP hydrochloride；2-Methyl-6-(2-phenylethynyl)pyridin-1-ium;chloride；2-methyl-6-(2-phenylethynyl)pyridin-1-ium;chloride
• CAS: 219911-35-0
• 化学式: C₁₄H₁₁N*ClH
• 分子量: 229.709
• InChiKey: PKDHDJBNEKXCBI-UHFFFAOYSA-N

物化性质

• 熔点：
  145-146℃
• 溶解度：
  二甲基亚砜：10 毫克/毫升

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  -20℃

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Methyl-2-(phenylethynyl)pyridine hydrochloride
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 219911-35-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : MPEP
Formula : C14H11N · HCl
Molecular Weight : 229,70 g/mol
CAS-No. : 219911-35-0
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong acids, Strong bases
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

生物活性

MPEP Hydrochloride 是一种有效的、选择性的、非竞争性的、口服有效的且具有系统活性的 mGlu5 受体拮抗剂，完全抑制 quisqualate 刺激的磷酸肌醇水解的 IC50 值为 36 nM。此外，MPEP Hydrochloride 还表现出抗焦虑或抗抑郁活性。

靶点

mGluR5 IC50: 36 nM

体外研究

在高浓度（100 mM）下，MPEP 在人类 mGlu2、-3、-4a、-7b 和 -8a 受体上均未表现出激动剂或拮抗剂活性。同样，在低浓度（10 μM）下，MPEP 也未在人 mGlu6 受体上表现相关活性。

体内研究 焦虑样效应

• MPEP (1-30 mg/kg) 在冲突饮水测试、悬尾测试以及小鼠的四板试验中表现出抗焦虑样的效果。
• MPEP (1-20 mg/kg) 可缩短小鼠悬尾测试中的不动时间，但对大鼠的行为绝望测试无效。
• 30 mg/kg ip 的 MPEP 在四板试验中小幅度但显著地增加了受惩罚的穿越次数（增加 39%），而较低剂量的化合物（3 和 10 mg/kg）在该测试中未影响受惩罚的穿越次数。
• 1、10 和 20 mg/kg 的 MPEP 显著减少了小鼠悬尾测试中的不动时间，其效果与阳性标准药物伊米替林（20 mg/kg）相似。

实验动物模型

• 动物：雄性 Wistar 大鼠 (体重 200 ± 250 g)。

• 给药方式：ip 或 po。

• 管理剂量：0.3、1 和 10 mg/kg，i.p。（冲突饮水测试）。

• 结果：在 0.3 mg/kg 剂量下无显著效果；而在 1 和 10 mg/kg 的 i.p. 给药下，明显（F (3,30) = 11.193, P < 0.001）增加了实验会话中接受的电击次数（分别增加 330% 和 507%）。

• 动物：雄性 Wistar 大鼠 (体重 200 ± 250 g)。

• 给药方式：ip 或 po。

• 管理剂量：1、3 和 10 mg/kg，i.p. 或 10 和 30 mg/kg, p.o。（悬尾测试）。

• 结果：在 1 mg/kg i.p. 下未改变进入和留在开放臂的时间。但在 3 和 10 mg/kg 的 i.p. 给药下显著（F (3,24) = 22.978, P < 0.001）剂量依赖性地增加了在开放臂的停留时间（分别增加至 45% 和 74%），和进入开放臂的比例（分别增加至 48% 和 68%，F(3,24) = 5.678, P < .01）。在剂量为 30 mg/kg po，但不是 10 mg/kg 的情况下，显著增加了开放臂停留时间的百分比和进入开放臂的比例（分别增加至 64%，F (2,16) = 14.249, P < 0.001）。口服给药在所用剂量下均未改变总入次数或总留在各类型手臂中的时间。

反应信息

• 作为产物：
  描述：

  2-甲基-6-(苯乙炔)吡啶盐酸盐 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 2-甲基-6-苯基乙炔基吡啶盐酸盐
  参考文献：
  名称：

  [EN] USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD
  [FR] EMPLOI D'ANTAGONISTES DE MGLUR5 POUR LE TRAITEMENT DU REFLUX GASTRO-OESOPHAGIEN

  摘要：

  本发明涉及使用代谢型谷氨酸受体5拮抗剂来抑制短暂性下食管括约肌松弛。本发明的另一个方面是使用代谢型谷氨酸受体5拮抗剂治疗胃食管反流病，以及治疗反流和哮喘。

  公开号：

  WO2004000316A1

文献信息

• Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles
  申请人：Chiesa Maria Vittoria

  公开号：US20080280855A1

  公开（公告）日：2008-11-13

  The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b. The compounds of the formula 1-a and the compounds of the formula 1-b, in which the substituents R1, R2, R3, and Ar have the meanings indicated in the description, are valuable intermediates for the preparation of pharmaceutically active compounds.

  本发明涉及一种合成公式1-a化合物和公式1-b化合物的方法。公式1-a化合物和公式1-b化合物中，取代基R1、R2、R3和Ar的含义如描述中所示，是制备药物活性化合物的有价值中间体。
• Spiro-benzimidazoles as inhibitors of gastric acid secretion
  申请人：Zimmermann Peter Jan

  公开号：US20090093473A1

  公开（公告）日：2009-04-09

  The invention provides compounds of the formula (I) In which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

  该发明提供了公式（I）中的化合物，其中取代基和符号如描述中所定义。这些化合物可以抑制胃酸的分泌。
• COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS
  申请人：Campbell David

  公开号：US20120046283A1

  公开（公告）日：2012-02-23

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of neuropsychiatric conditions.

  本文提供了PAK抑制剂及其在治疗神经精神疾病方面的应用方法。
• 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
  申请人：Vollrath Benedikt

  公开号：US20120270866A1

  公开（公告）日：2012-10-25

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗中枢神经系统疾病，如神经精神障碍的方法。
• METHODS FOR TREATING SCHIZOPHRENIA
  申请人：Lichter Jay

  公开号：US20120184547A1

  公开（公告）日：2012-07-19

  Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from schizophrenia.

  提供PAK抑制剂。此外，还提供了用于治疗患有精神分裂症的个体的组合物和方法。